COMMUNIQUÉS West-GlobeNewswire

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
07/08/2026
Reports second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed [...]
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
07/08/2026
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
07/08/2026
Tokyo, Japan and Cambridge, UK, 7 August 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June [...]
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
07/08/2026
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global [...]
National Health Sanitary Association Announces United Nations Procurement and Partnership Registration
07/08/2026
Washington State-based public health organization expands international cooperation framework for disease prevention, health education, humanitarian assistance and community health development. WASHINGTON, Aug. 07, 2026 [...]
CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
07/08/2026
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells Lehi Utah, Aug. 06, 2026 [...]
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
07/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop [...]
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
07/08/2026
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced [...]
Better U Expands 2026 Patient Eligibility, Safety and Treatment Access Information for At-Home Ketamine Therapy
07/08/2026
Online eligibility screening, off-label compounded oral ketamine and licensed pharmacy fulfillment explained, with SPRAVATO esketamine offered separately WEST HOLLYWOOD, Calif.,, Aug. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b [...]
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second [...]
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
06/08/2026
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented [...]
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
06/08/2026
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
06/08/2026
Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics [...]
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
06/08/2026
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
06/08/2026
Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of [...]
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
06/08/2026
First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
06/08/2026
PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the [...]
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 [...]

Pages